Septerna (NASDAQ:SEPN) Stock Rating Cut to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Septerna from “Hold” to “Sell,” though analyst sentiment overall remains “Moderate Buy,” with a consensus price target of $56.44.
• Septerna’s latest quarterly results missed expectations: it reported a loss of $0.57 per share versus the $0.42 loss analysts forecast, and revenue of $18.88 million versus the $20.78 million estimate.
• Company insiders sold 89,153 shares worth about $4.21 million over the last quarter, including a director’s sale of 81,820 shares.

Septerna (NASDAQ:SEPN - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other research analysts have also commented on SEPN. Guggenheim lifted their price target on shares of Septerna from $51.00 to $65.00 and gave the company a "buy" rating in a report on Friday, November 6th. JPMorgan Chase & Co. increased their price objective on shares of Septerna from $38.00 to $48.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 19th. Weiss Ratings reissued a "sell (d-)" rating on shares of Septerna in a report on Thursday, October 15th. Raymond James Financial restated a "strong-buy" rating and issued a $49.00 target price on shares of Septerna in a research note on Tuesday, August 11th. Finally, Wells Fargo & Company upped their target price on Septerna from $50.00 to $61.00 and gave the company an "overweight" rating in a report on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Septerna has an average rating of "Moderate Buy" and a consensus price target of $56.44.

Septerna Trading Up 1.8%

Shares of NASDAQ SEPN opened at $42.60 on Friday. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of -33.02 and a beta of 2.20. Septerna has a twelve month low of $19.69 and a twelve month high of $53.34. The business has a 50 day simple moving average of $40.46 and a 200-day simple moving average of $33.12.

Septerna (NASDAQ:SEPN - Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.15). The firm had revenue of $18.88 million for the quarter, compared to the consensus estimate of $20.78 million. Septerna had a negative return on equity of 14.98% and a negative net margin of 61.29%. As a group, equities analysts predict that Septerna will post -1.45 earnings per share for the current year.

Insider Transactions at Septerna

In other news, Director Alan Ezekowitz sold 81,820 shares of the firm's stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $48.09, for a total transaction of $3,934,723.80. Following the transaction, the director directly owned 35,600 shares of the company's stock, valued at approximately $1,712,004. This trade represents a 69.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Daniel Long sold 3,333 shares of the company's stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total transaction of $126,087.39. Following the completion of the sale, the senior vice president directly owned 96,412 shares of the company's stock, valued at $3,647,265.96. The trade was a 3.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 89,153 shares of company stock valued at $4,210,451. 5.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Sterling Capital Management LLC raised its holdings in Septerna by 215.0% during the third quarter. Sterling Capital Management LLC now owns 630 shares of the company's stock worth $25,000 after purchasing an additional 430 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Septerna during the 3rd quarter valued at $93,000. Covestor Ltd increased its position in shares of Septerna by 19.0% during the 3rd quarter. Covestor Ltd now owns 2,526 shares of the company's stock valued at $98,000 after purchasing an additional 403 shares during the period. The Manufacturers Life Insurance Company bought a new stake in shares of Septerna in the 2nd quarter worth $211,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in shares of Septerna in the 3rd quarter worth $232,000.

Trending Headlines about Septerna

Investors following SEPN have been watching these headlines:

• Positive Sentiment: Analysts raised expectations for Septerna’s SEP-479 program, prompting a fair-value increase. The more optimistic outlook could support investors’ expectations for the company’s pipeline. Septerna fair-value lift as analysts raise SEP-479 expectations
• Positive Sentiment: Stifel Nicolaus raised its price target on SEPN, while another report said the shares reached a new 52-week high following an analyst upgrade—signals that may reinforce positive sentiment. Stifel Nicolaus price-target boost Shares reach a 52-week high following analyst upgrade
• Neutral Sentiment: HC Wainwright maintained its Buy rating and $60 target. Its revisions were mixed: it raised its FY2027 loss estimate to a smaller loss of $1.34 per share, but lowered its FY2026 estimate to a larger loss of $1.48 per share and also cut estimates for Q4 2026 and Q1 2027. Septerna analyst and stock information

About Septerna

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.